J
Joel Shapiro
Researcher at Erasmus University Rotterdam
Publications - 41
Citations - 3253
Joel Shapiro is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Chemoradiotherapy & Neoadjuvant therapy. The author has an hindex of 22, co-authored 37 publications receiving 2559 citations. Previous affiliations of Joel Shapiro include Rochester General Health System & Utrecht University.
Papers
More filters
Journal ArticleDOI
Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline
Mary Pulvino,Luojing Chen,David Oleksyn,Jing Li,George Compitello,Randy Rossi,Stephen A. Spence,Vijaya Balakrishnan,Craig T. Jordan,Craig T. Jordan,Brian Poligone,Carla Casulo,Richard Burack,Joel Shapiro,Steven H. Bernstein,Jonathan W. Friedberg,Raymond J. Deshaies,Hartmut Land,Jiyong Zhao +18 more
TL;DR: It is demonstrated that doxycycline inhibits the growth of DLBCL cells both in vitro and in mouse xenograft models, and the deneddylating activity of COP-9 signalosome (CSN) is revealed as a novel target of doxy cycline and it is suggested that doXYcycline may represent a promising therapeutic agent forDLBCL and other non-Hodgkin lymphomas subtypes.
Journal ArticleDOI
Nomogram for predicting pathologically complete response after neoadjuvant chemoradiotherapy for oesophageal cancer
Eelke L A Toxopeus,Daan Nieboer,Joel Shapiro,Katharina Biermann,Ate van der Gaast,Carolien M. van Rij,Ewout W. Steyerberg,Joseph Jan Baptiste van Lanschot,Bas P. L. Wijnhoven +8 more
TL;DR: A nomogram for the prediction of pathologically complete response after neoadjuvant chemoradiotherapy was developed, with a reasonable predictive power, but needs external validation before it can be used for individualised clinical decision-making.
Journal ArticleDOI
Patients' preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancer
Bo Jan Noordman,E.W. de Bekker-Grob,P. P. L. O. Coene,E. van der Harst,Sjoerd M. Lagarde,Joel Shapiro,B. P. L. Wijnhoven,J. J. B. van Lanschot +7 more
TL;DR: Factors that influence patients' preferences, and trade‐offs that patients are willing to make in their choice between surgery and active surveillance were investigated here.
Journal ArticleDOI
Prognostic Value of Pretreatment Pathological Tumor Extent in Patients Treated With Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal or Junctional Cancer.
Joel Shapiro,Katharina Biermann,David van Klaveren,G. Johan A. Offerhaus,Fiebo J.W. ten Kate,Sybren L. Meijer,Mark I. van Berge Henegouwen,Ewout W. Steyerberg,Bas P. L. Wijnhoven,J. Jan B. van Lanschot +9 more
TL;DR: Pretreatment pathological staging should be considered useful as a new staging parameter for esophageal cancer and could also be of interest for other tumor types.
Journal ArticleDOI
Thoracic Involvement With Pheochromocytoma: A Review
TL;DR: A case of endobronchial metastases in a 37-year-old woman known to have a recurrent extra-adrenal pheochromocytoma is reported, believed to be the first reported case ofEndobron chial phechromocyToma reported in the world.